References
- Pariser S. Women and mood disorders. Menarche to menopause. Ann Clin Psychiatry 1993;5:249–54.
- Pluchino N, Cubeddu A, Giannini A, et al. Progestogens and brain: an update. Maturitas 2009;62:349–55.
- Brucker C, Hedon B, Sien H, et al. Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen. Contraception 2010;81:501–9.
- Pelissier C, Basdevant A, Conard J, et al. Progestogen contraception using chlormadinone acetate in women presenting high vascular risk. A gynecoendocrine, metabolic and vascular study. Contracept Fertil Sex (Paris) 1987;15:45–54.
- Schramm G, Steffens D. Contraceptive efficacy and tolerability of chlormadinone. Clin Drug Investig 2002;22:221–31.
- Heskamp ML, Schramm GA. Efficacy of the low-dose combined oral contraceptive chlormadinone acetate/ethinylestradiol: physical and emotional benefits. Contraception 2010;81:49–56.
- Martinez F, Avecilla A. Combined hormonal contraception and venous thromboembolism. Eur J Contracept Reprod Health Care 2007;12:97–106.
- Winkler UH, Daume E, Sudik R, et al. A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 mu(g) ethinylestradiol and either 2 mg chlormadinone acetate or 150 mu(g) desogestrel. Eur J Contracept Reprod Health Care 1999;4:145–54.
- Zahradnik HP, Hanjalic-Beck A, Groth K. Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrhea: a review. Contraception 2010;81:185–96.
- Schramm GAK, Waldmann-Rex S. Effects of 2 mg chlormadinone acetate/0.03 mg ethinylestradiol in primary dysmenorrhoea: the BEDY (Belara(R) evaluation on dysmenorrhea) study-an open non-comparative, non-interventional observational study with 4,842 women. J Reproduktionsmed Endokrinol 2010;7:112–18.
- Schramm G, Heckes B. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The contraceptive switch study. Contraception 2007;76:84–90.
- Worret I, Arp W, Zahradnik HP, et al. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/ACM (Belara1) and EE/LNG (Microgynon1). Dermatology 2001;203:38–44.
- Sabatini R, Orsini G, Cagiano R, Loverro G. Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents. Contraception 2007;76:142–7.
- Pluchino N, Lenzi E, Merlini S, et al. Selective effect of chlormadinone acetate on brain allopregnanolone and opioids content. Contraception 2009;80:53–62.
- Martín-García S, Darbra M. Implicación de los neuroesteroides en la conducta normal y patológica. Revisión en neurociencia. Rev Neurol 2007;44:661–76.
- Zahradnik HP, Hanjalic-Beck A, Schilling Redlic A. Beneficios no anticonceptivos de 0,02 mg de etinilestradiol/2 mg de acetato de clormadinona administrados en un régimen de 24 + 4 días. Rev Chil Obstet Ginecol 2011;76:344–53.